The trial will include patients with non-small cell lung, breast, ovarian, gastric, esophageal, and colorectal cancers.
With this approval, patients who receive the anti-amyloid drug biweekly for 18 months can then consider switching to a monthly dosing regimen.
In a Phase I/II trial, patients with X-linked chronic granulomatous disease will receive a treatment created using a new ...
HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run ...
NEW YORK – BlossomHill Therapeutics on Wednesday said it has begun treating lung cancer patients with EGFR- or HER2-mutated tumors with its OMNI-EGFR inhibitor BH-30643 in a Phase I/II trial. The ...
NEW YORK – Axovia Therapeutics and Viralgen on Wednesday said they have entered into a partnership to advance development and manufacturing for AXV-101, a gene therapy designed to treat retinal ...
The Shanghai-based firm will test the gene therapy candidate in patients between 4 and 9 years old with Duchenne muscular dystrophy.
The firm said it has received positive feedback from the FDA on the design of a Phase III trial of ELI-002 in KRAS-mutant pancreatic cancer.
The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and ...
Their study showed that DCIS patients with pathogenic variants in BRCA1/2 and PALB2 had a higher risk of developing invasive breast cancer than those without.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback